Cargando…

Ultra-performance liquid chromatography-tandem mass spectrometric method for quantitation of the recently Food and Drug Administration approved combination of vaborbactam and meropenem in human plasma

A parenteral medical combination containing vaborbactam and meropenem is used mainly to treat complicated urinary tract infections. A novel ultra-performance liquid chromatography tandem mass spectrometric method was developed for the sensitive determination of both compounds in human plasma. Sample...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kammoun, Ahmed K., Khedr, Alaa, Khayyat, Ahdab N., Hegazy, Maha A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society 2020
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428257/ https://www.ncbi.nlm.nih.gov/pubmed/32874656 http://dx.doi.org/10.1098/rsos.200635

Ejemplares similares

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring
por: Barone, Rossella, et al.
Publicado: (2023)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections
por: Lai, Chih-Cheng, et al.
Publicado: (2019)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
por: Castanheira, Mariana, et al.
Publicado: (2023)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

1676. PK, Safety and Tolerability of VABOMERE(®) (meropenem-vaborbactam) in Infants, Children and Adolescents
por: Bokesch, Paula M, et al.
Publicado: (2023)

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma
por: Ogawa-Morita, Tomoko, et al.
Publicado: (2017)

Accumulation of oxysterols in the erythrocytes of COVID-19 patients as a biomarker for case severity
por: Khedr, Alaa, et al.
Publicado: (2023)

521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa
por: Patel, Twisha S, et al.
Publicado: (2019)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
por: Trang, M., et al.
Publicado: (2021)

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date
por: Herald, Fischer, et al.
Publicado: (2023)

A Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneously Determining Meropenem and Linezolid in Blood and Cerebrospinal Fluid
por: Berska, Joanna, et al.
Publicado: (2024)

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
por: Sime, Fekade B., et al.
Publicado: (2018)

Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
por: Duda-Madej, Anna, et al.
Publicado: (2023)

Multi-Steps Fragmentation-Ion Trap Mass Spectrometry Coupled to Liquid Chromatography Diode Array System for Investigation of Olaparib Related Substances
por: Khedr, Alaa, et al.
Publicado: (2019)

A rapid and sensitive liquid chromatography–tandem mass spectrometric assay for duloxetine in human plasma: Its pharmacokinetic application
por: Gajula, Ramakrishna, et al.
Publicado: (2013)

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
por: Sun, Dongxu, et al.
Publicado: (2017)

1589. Activity of Meropenem-Vaborbactam and Comparators against Globally Disseminated Klebsiella pneumoniae Sequence Type 258
por: Shorttidge, Dee, et al.
Publicado: (2020)

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study
por: Tumbarello, Mario, et al.
Publicado: (2022)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
por: Shrief, Raghdaa, et al.
Publicado: (2022)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)

Analysis of ent-kaurenoic acid by ultra-performance liquid chromatography-tandem mass spectrometry
por: Miyazaki, Sho, et al.
Publicado: (2015)

Analysis of Flavonoids in Dalbergia odorifera by Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry
por: Zhao, Xiangsheng, et al.
Publicado: (2020)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
por: Carvalhaes, Cecilia G., et al.
Publicado: (2020)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
por: Bhowmick, Tanaya, et al.
Publicado: (2020)

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018
por: Gaibani, Paolo, et al.
Publicado: (2021)

Correction to: 1589. Activity of Meropenem-Vaborbactam and Comparators against Globally Disseminated Klebsiella pneumoniae Sequence Type 258
Publicado: (2022)

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
por: Shortridge, Dee, et al.
Publicado: (2022)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
por: Marino, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gv3kv0nba97vtslr9qkbfbq4vp